Decoy Therapeutics Inc. (DCOY) Stock Forecast
DCOY analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $3.00 average of analyst targets
- Upside to target
- +156.4% from the latest close
- Next earnings
- November 13, 2026
- 52-week range
- $1.17 – $48.60
DCOY analyst ratings
1 analystsNumber of analysts at each rating.
DCOY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DCOY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.59 | −$2.59 | −$2.59 | −$21.72 | +88.1% | 1 |
| Current fiscal year (2026) | −$8.96 | −$8.96 | −$8.96 | −$129.10 | +93.1% | 1 |
| Next fiscal year (2027) | −$8.28 | −$8.28 | −$8.28 | −$8.96 | +7.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DCOY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | — |
| Current fiscal year (2026) | $0 | $0 | $0 | — | — |
| Next fiscal year (2027) | $0 | $0 | $0 | — | — |
DCOY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DCOY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$3.12 | $0.00 | $0.00 | $0.00 | −$2.59 | −17.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$12.96 | $0.00 | $0.00 | $0.00 | −$8.96 | −30.9% | 1 up · 0 down |
| Next fiscal year (2027) | −$19.32 | $0.00 | $0.00 | $0.00 | −$8.28 | −57.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DCOY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DCOY beat in 8 of 10.
What analysts expect from DCOY
1 analysts cover Decoy Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.00, 156.4% above the latest close of $1.17. Analysts expect earnings of −$8.96 per share for 2026, +93.1% from a year earlier. For 2027 the average estimate is −$8.28 per share. Decoy Therapeutics beat the EPS estimate in 8 of the last 10 quarters.
Related: DCOY income statement, DCOY key metrics, DCOY chart. See the DCOY stock overview for the latest quote and news.
DCOY forecast FAQ
What is Decoy Therapeutics's price target?
The average analyst price target for Decoy Therapeutics is $3.00, 156.4% above the latest close of $1.17.
Is Decoy Therapeutics a buy, hold or sell?
Of 1 analysts covering Decoy Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Decoy Therapeutics's EPS forecast?
Analysts forecast −$8.96 per share for 2026 (range −$8.96 to −$8.96); for 2027 the estimate is −$8.28.
When does Decoy Therapeutics report earnings?
Decoy Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
Does Decoy Therapeutics usually beat earnings estimates?
Decoy Therapeutics reported EPS at or above the analyst estimate in 8 of the last 10 quarters.